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The first-line management of metastatic prostate cancer is hormonal therapy. However, resistance to this treatment
will emerge within an average of 24 months. Our purpose was to determine the course of metastatic prostate
cancer under treatment.
A total of 56 patients who were diagnosed with metastatic prostate cancer were enrolled. As initial management, 3
kinds of hormonal therapy consisting of bilateral orchiectomy (BSO) alone, BSO + anti-androgene (AA) and LH-RH +
AA were applied. The patients were followed until the emergence of hormone resistance. Serum PSA levels at the
time of first diagnosis, post-treatment nadir PSA levels, time to nadir PSA, time to hormonal resistance and PSA
levels at hormonal resistance were assessed, retrospectively. The localization and number of metastases and the
survival term from the beginning of the emergence of hormone resistance until death were investigated
No significant differences could be established between the groups. The mean time to reach hormone refractory
status was 30.3 months for the whole study group. The average term of survival was 42.7 months for the whole
group. Distance metastases were found in 8 patients during follow-up.
There were no statistical differences between the groups in terms of treatment modalities applied for metastatic
prostate cancer. Patients with androgen independent prostate cancer demonstrated progression despite chemical
or surgical castration, and had poor prognosis. Initial hormonal therapy failed after an average of 2 years in
metastatic prostate cancer.
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Most of the prostate cancers (PCa) are, at least at the be-
ginning, endocrine-dependent tumors. Therefore, hormo-
nal therapy is still a first-choice treatment (Chen et al.
2008). The first effects to hormonal treatment with med-
ical or surgical castration are quite considerable, with
rapid biochemical responses, as evaluated by declines in
levels of the serum marker, prostate-specific antigen (PSA)
(Di Lorenzo et al. 2010; Chi et al. 2009). However, most
patients showing a first response to hormonal therapy
for PCa will progress to a castration-insensitive phase of
the disease that continues a much poorer prognosis
(Chi et al. 2009).
The true is that androgens have an important role in the
whole clinical course of Pca, even when a patient meets
castration-resistance criteria (Pinto 2013). Luteinizing* Correspondence: draslandemir@yahoo.com
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in any medium, provided the original work is phormone (LH) and follicle-stimulating hormone (FSH) are
of considerable roles in PCa progression. Specifically, LH
expression in PCa tissues has been associated with meta-
static disease with a poor prognosis, while FSH has been
related to stimulate prostate cell growth in hormone-
refractory PCa (Kluth et al. 2013). Endocrine therapy is the
standard treatment for metastatic PCa, but in its progess an
androgen independence status can occurs. As endocrine
management, primary androgen deprivation therapy (ADT)
is the standard of care, usually with a long-releasing LHRH
analogue or antagonist (Pagliarulo et al. 2012).
The aim of our study was to determine the course of
the disease in patients with initial metastatic PCa.Results
A total of 56 patients were enrolled. In this study, the
median age of the patients was 70 (min. 59 – max. 93).
BSO alone was performed in 12 patients (21.7%), ad-
junctive antiandrogen therapy was given to 18 patientsn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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drogen therapy were given to 26 patients (46.1%). No
statistically significant differences could be established
between the groups according to the parameters of our
study (Table 1). The mean PSA (ng/ml) values before
treatment were 171, 383.7, and 626.5, respectively. The
Gleason Scores (GS) of all groups were 7. The mean time
to the emergence of hormone refractory status was found
to be 30.3 months for the whole study group. The average
survival was 42.7 months (min. 9-max. 120) in the whole
group. Mean survival time (month) were 45, 45.25, and
34.25, respectively. Distance metastases were found in 8
patients during follow-up. The prognosis of these patients
was poor.
Discussion
Monotherapy and combined therapy are the hormonal
management modalities. The first one contains castration
or anti-androgens treatment, and the second one includes
maximum or complete androgene blockage (MAB or CAB)
with castration (medical or surgical) and anti-androgens.
However, a refractory status to these treatment will pro-
gress within an average of 2 years. Poor prognosis and
death from the disease within 18–24 and 22 months
have been reported by some researchers in the literature
(Crawford et al. 1989; Kelly et al. 2010) but in the begin-
ning, estimates of median survival for patients with
hormone-refractory PCa were 7–12 months (Hussain et al.
1994). When the patients progress in front of continued
androgen ablation, they are named to have hormone-
refractory prostate cancer or metastatic castrate-resistant
prostate cancer (mCRPC) (Martel et al. 2003).
Most patients with PCa at the organ confined level
have an excellent prognosis after radical prostatectomy
and/or radiation therapy. A significant fraction (20%-
40%) of patients who undergo primary therapy experi-
ence biochemical progression, and 30–70% of those with
biochemical relapse progress to the metastatic status




The PSA (ng/ml) values before teratment 91 171
Gleason score 7 7,33
The nadir PSA (ng/ml) after treatment 1,3 31,01
The time to the nadir PSA (months) 3 5,9
The time to hormonal resistance (months) 18,7 32,77
The PSA (ng/ml) at the hormonal resistance 103,5 124,2
Survival (months) 25 45
All p values >0,05.1999). Usually, patients with hormone-refractory PCa
may apply with symptoms associated with metastases,
especially bone, lymph nodes and other urinary metasta-
ses, but the first sign is generally, an increased PSA
levels despite to the treatment (Martel et al. 2003;
Sammon et al. 2013).
The population of PCa with distant metastasis is het-
erogeneous (European Association of Urology Guide-
lines 2013). One of the poor prognostic factors was the
PSA level greater than 65 ng/ml (Chi et al. 2009). Ac-
cording to the results of our study, mean PSA (ng/ml)
values before treatment were 171, 383.7, and 626.5, re-
spectively. The GS of all groups in our study were 7.
The choice between orchiectomy and oestrogens are
the standard treatment for advanced PCa (Murphy et al.
1983; Sharifi 2009). It is well known that the initial de-
velopment of PCa is dependent on androgens; therefore,
the first-line management of this situation is endocrine
management. First-line treatment for advanced PCa is
ADT, usually with agents that inhibates gonadotropins
through a pituitary mechanism. Gonadotropin-releasing
hormone agonists and antagonists both inhibates go-
nadal release of testosterone, although their activity pro-
files differ (Murphy et al. 1983; Kluth et al. 2013).
ADT down-regulates the androgen receptor (AR) in the
tumor but the response in advanced disease is not per-
manent, a progression may occur as CRPC. Although
serum testosterone levels decrease significantly with ADT,
CRPC development largely depends on AR activity (Sharifi
2009). Secondary hormonal therapies are then often used
to further lessen AR-driven. These secondary hormonal
managements either further deplete adrenal or intratu-
moral androgens synthesis, or directly and competitively
antagonize AR (Sharifi 2009).
The median survival time for patients with metastatic
androgen-independent PCa is approximately 1 or 2 years
(Hussain et al. 1994; Kelly et al. 2010). In most studies
in the literature, no statistically significant differences






Median Mean Median Mean Median Mean
143 383,7 115 626,5 110 423,8
7 7,5 7 7,52 7 7,4
3,6 37,47 2,4 7,87 2,71 21,68
4,5 6,45 8,5 9,27 6 7,44
17 26,48 21 27,3 20 30,28
54 163,7 38,5 890,6 54 489,9
47 45,25 32 34,35 34 42,67
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metastatic PCa. The results of our study are similar to
those in the literature. The Median and mean survival
time (month) in our study were 25/45, 47/42.25, and 32/
34.35, respectively.
Robinson et al. compared the alternatives of orchiec-
tomy and maximal androgen blockage with 1 mg di-
ethylstilbestrol (DES) in 1995 and declared no difference
in terms of progression rate and survival between the
two groups (Robinson et al. 1995). In another study con-
ducted by Mikkola et al., orchiectomy and parental poly-
estradiol phosphate were compared and no difference was
reported in terms of progression and survival follow-up
for 2 years (Mikkola et al. 1998). Laufer et al. found no
benefits in the use of combined androgen blockade (CAB)
with medical or surgical castration (Laufer et al. 2000). In
addition, a non-steroidal antiandrogen for metastatic PCa
was investigated in 20 randomized trials by Crawford et al.
which led to the finding that there is a 5% improvement in
the percentage of men surviving 5 years (30% vs. 25%)
with combined androgen blockade with nonsteroidal anti-
androgens, as well as improvements in progression-free
survival at 1 year (Crawford et al. 1989).
The patients with metastatic PCa ought to be in-
formed of the potential benefits, toxicities and out-of
pocket expenditures about managements modalities
(Schmitt et al. 2001; Prostate Cancer Trialists’ Collo-
borative Group 2000). Gastrointestinal, ophthalmological
and hematological side effects are worse with CAB.
Although LHRH analogues and non-steroidal anti-
androgens have the highest estimated quality-adjusted
survival, there is an increased cost of more than US$1 mil-
lion per quality-adjusted life-year for CAB over orchiec-
tomy alone (European Association of Urology Guidelines
2013). In a SWOG study published in 1998, although
there was no statistical difference, using MAB decreased
the risk of mortality about 9% compared with orchiec-
tomy alone. In addition, two meta-analyses have de-
clared that there is an increase in response rate using
MAB with non-steroidal antiandrogen compared to
mere castration (Prostate Cancer Trialists’ Colloborative
Group 2000; Caubet et al. 1997). On the other hand, the
same studies mentioned that there was also an increase in
time to progression when using MAB with non-steroidal
antiandrogen compared with other managements (Caubet
et al. 1997; Glashon & Robinson 1981).
Fossa et al. have mentioned responses to flutamide in
some patients in whom previous endocrine manage-
ments failed, and found that this correlated with in-
creased survival (Fossa et al. 1990). On the other hand,
Andrew et al. have established that orchiectomy as a sec-
ondary hormonal management following relapse on anti-
androgen does produce a response in terms of PSA level
and symptoms in some patients (Andrew et al. 2001). Inthe only published randomized controlled trials (RCT),
there was no significant difference in OS for flutamide
monotherapy compared in bone metastatic patients with a
PSA <100 ng/ml. But at a higher PSA, flutamide was infer-
ior. (European Association of Urology Guidelines 2013).
Bicalutamide, 150 mg once daily, it has been compared
to medical or surgical castration in two large prospective
RCTs with identical study designs, including patients
with locally advanced or metastatic PCa; the analysis
found that in metastatic patients, there was an improve-
ment in OS with medical or surgical castration, although
the difference in median survival between the groups
was only 6 weeks (Tyrrell et al. 1998).
According to our results, there is no statistical differ-
ence in terms of survival between the hormonal treat-
ment modalities that have been applied for metastatic
PCa in the literature, but we must pay attention to the
status of each patient with advanced PCa, such as psy-
chological state and tolerance to the side effects of the
treatment modalities, since the quality-of-life is para-
mount. Antiandrogen therapy has remained the main-
stay in the treatment of metastatic PCa. To reduce the
testosterone level in blood, both oestrogens and bilateral
orchiectomy can be use effectively (Martel et al. 2003).
However, oestrogens have obvious disadvantages and
particularly cardiovascular, even life-threatening, side ef-
fects need to take into the consideration (Glashon &
Robinson 1981). On the other hand, the underestimation
of the psychological side effects of bilateral orchiectomy
is possible. Therefore, the advantages of LH-RH ana-
logues have led to the new views in the management of
PCa. Superactive LH-RH analogues effectively reduce
plasma testosterone to castrate levels (Jacobi & Wender-
oth 1982). Therefore, these drugs can be considered as
the first choice alternatives to oestrogens or orchiec-
tomy, but we believe that not only is cost-effectiveness
an important issue that should be considered for pa-
tients who do not have any health insurance, but the
socio-cultural level of patients is also important in terms
of accommodation to the treatment. Namely, if the
socio-cultural and economic level of the patient is low,
then BSO may be the first choice for treatment.
In addition to these findings, the development of a
hormone-refractory state in patients with advanced PCa
is inevitable. Initial androgen ablation can provide, on
average, 18 months of biochemical response. There has
been an interest in utilizing antiandrogen monotherapy
in these patients initially to preserve quality-of-life.
If the biochemical relapse does occur under treatment
of antiandrogen monotherapy, to know whether further
hormonal manipulation will provide any benefit is im-
portant. Scher et al. have declared that patients who had
a biochemical relapse on maximal androgen blockade
and then had a response to antiandrogen withdrawal,
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androgen (Scher et al. 1997). It has been suggested that
stopping of androgen deprivation before the progression
of androgen resistant situation would mean that any
subsequent tumor growth would be sustained by the
proliferation of androgen-sensitive stem cells. The stem
cells should therefore be susceptible one more time to
androgen withdrawal. Thus, intermittent androgen
blockade (IAD) would postpone the emergence of the
androgen-resistant clone. In addition, preservation of
quality-of-life of patients under IAD treatment will
occur in terms of better tolerance of treatment; some-
times benefits in sexual function in off-treatment periods
and reduction in the cost of treatment will be provided.
However, IAD has not been reported to be related to
prolonged hormone-sensitive status or an increase in OS
(European Association of Urology Guidelines 2013).
We know that, currently, there is no standard front-
line or second line therapy for these hormone refractory
patients. For that reason, we must pay attention the pa-
tients’ quality-of-life when deciding on the method of
treatment. At this point, the expectations of the patients
are of great importance. In our opinion, treatment mo-
dalities that have reversible side effects should be chosen
in order to evaluate the tolerance of the patients at the
beginning of management. For that reason, medical
treatment modalities should be chosen primarily in
order to avoid the psychological side effects of surgery
such as empty scrotum, hot flashing, etc.
Average survival of patients with metastatic PCa follow-
ing relapse who do not undergo further treatment is
14 months (Matzkin et al. 1993). Unfortunately, despite all
treatments, treatment failure occurs within 2 years of initial
management. Treatment options for hormone refractory
disease include intensive supportive care, radiotherapy,
biphosphonates, second-line hormonal manipulations,
cytotoxic chemotherapy and investigational agents. Chemo-
therapeutic agents have yielded improved response rates
and palliative benefit, but not improved survival (Hussain
et al. 1994; Murphy et al. 1983; Kantoff et al. 1999; Robinson
et al. 1995). Therefore, new studies must focus on new
agents in order to improve survival, time to progression and
quality-of-life. We also believe that psychological support
should be given at the time of progression to the hormone
refractory stage for the sake of quality-of-life.
Conclusion
As a conclusion; according to our results, there was no
statistical difference between the hormonal treatments
that were applied in metastatic prostate cancer in terms
of the above mentioned parameters. Patients with andro-
gen independent prostate cancer demonstrate progression
of the disease despite chemical or surgical castration, and
have poor prognosis.Methods
A database of 56 patients who had a metastatic PCa
diagnosis and received hormonal therapy as initial man-
agement, which was applied until the emergence of hor-
mone resistance, was retrospectively reviewed in order
to understand the course of the disease. The patients
were categorized into 3 groups according to the type of
applied treatment modality. These groups comprised bi-
lateral subcapsular orchiectomy (BSO) alone, bilateral
subcapsular orchiectomy combined with anti-androgen
therapy, and LH-RH combined with anti-androgen. One
of these treatment modalities was applied to the patients
as initial management. Serum PSA levels at the time of
the first diagnosis, post-treatment nadir PSA levels, time
to nadir PSA, time to hormonal resistance and PSA
levels at hormonal resistance were assessed retrospect-
ively. In addition to these, the localization and number
of metastases and the term of survival from the begin-
ning of the emergence of hormone resistance until death
were investigated.
Statistical analysis
One-way ANOVA test, a parametric statistical test, was
used to compare the three groups with respect to the
normally distributed variables in our data. A probability
level of p < 0.05 was considered as significant.
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